HF-158K1 by HighField Biopharmaceuticals for Gastric Cancer: Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Gastric Cancer.

Ideaya showcases proof-of-concept data in a boost to synthetic lethality play

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 9, 2024

Teen Vaping Hits 10-Year Low in the U.S.

Fewer adolescents are vaping this year than at any point in the last decade, government officials reported Thursday, pointing to a shrinking number of high

September 6, 2024

ARCH backs lab instrument company that wants to help demystify how cells talk to each other

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.